What is Cytovation?
Emerging from over 15 years of rigorous research at the University of Bergen and Haukeland University Hospital, Cytovation is positioned at the intersection of tumor biology and synthetic chemistry. The company's core innovation, CyPep-1, functions as a first-in-class lytic agent designed to selectively target and disrupt the membranes of cancer cells. By leveraging the altered molecular composition of tumor cells, this mechanism not only induces direct cell death but also facilitates the release of tumor antigens, potentially triggering a robust, tumor-specific immune response. This dual-action approach—combining direct lysis with in-situ immunization—places Cytovation in a unique category within the competitive landscape of immuno-oncology, offering both injectable and topical therapeutic modalities for diverse solid tumor indications.
How much funding has Cytovation raised?
Cytovation has raised a total of $30.4M across 2 funding rounds:
Private Equity
$2.4M
Series A
$28M
Private Equity (2017): $2.4M, investors not publicly disclosed
Series A (2023): $28M, investors not publicly disclosed
Key Investors in Cytovation
Undisclosed Investor
An undisclosed institutional investor providing strategic backing to support the advancement of late-stage clinical biotechnology assets.
Undisclosed Investor
A private equity firm focused on long-term value creation within the life sciences and medical research sectors.
Undisclosed Investor
An investment group specializing in early-to-mid stage oncology research and development initiatives.
What's next for Cytovation?
With this major enterprise-level funding, Cytovation is well-positioned to transition its lead candidate, CyPep-1, through critical clinical trial phases. The strategic roadmap focuses on validating the safety and efficacy of its lytic agent in human subjects, while simultaneously refining its manufacturing processes for both cream and injectable formulations. As the company moves deeper into the clinical development lifecycle, the focus will shift toward establishing regulatory milestones and exploring potential partnerships with larger pharmaceutical entities. The current capital structure provides the necessary runway to expand the research team and bolster the intellectual property portfolio, ensuring that Cytovation remains at the forefront of synthetic peptide innovation in the global oncology market.
See full Cytovation company page
